8-K: Greenbrook TMS Reports Q3 2024 Results, Announces Acquisition by Neuronetics

Greenbrook TMS Inc. announced its Q3 2024 financial results, highlighted by a 9% increase in service revenue, and confirmed its acquisition by Neuronetics is expected to close in early December 2024.

Summary

• Greenbrook TMS Inc. reported a 9% increase in quarterly service revenue to $18.9 million for Q3 2024, compared to $17.4 million in Q3 2023.
• Year-to-date service revenue increased by 3% to $56.0 million, up from $54.4 million in the same period of 2023.
• The company recognized $0.2 million in other revenue in Q3 2024 related to a research collaboration agreement.
• Regional operating loss increased by 242% in Q3 2024 to $0.5 million, and by 303% to $1.8 million year-to-date, due to increased direct center and regional costs.
• Net loss decreased by 16% in Q3 2024 to $11.0 million, and by 6% to $33.3 million year-to-date.
• Greenbrook is expanding its Spravato offering to 82 treatment centers, medication management to 11 centers, and talk therapy in Florida and Missouri.
• The company's acquisition by Neuronetics is expected to close in early December 2024.
• A supplemental restructuring plan will close 23 treatment centers by the end of 2024, focusing on the remaining 95 centers.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is positive revenue growth and strategic expansion, the increasing losses and restructuring efforts indicate financial challenges. The acquisition by Neuronetics is a positive development, but the overall sentiment is neutral due to the underlying financial concerns.

Positives

• Service revenue increased by 9% in Q3 2024, showing growth in core operations.
• The company is expanding its treatment offerings with Spravato, medication management, and talk therapy.
• The acquisition by Neuronetics is expected to create a vertically-integrated organization with significant scale.
• The supplemental restructuring plan aims to improve operational efficiencies and profitability.

Negatives

• Regional operating loss increased significantly in Q3 2024 and year-to-date.
• Treatment volumes and new patient starts decreased in Q3 2024.
• The company is closing 23 treatment centers as part of a restructuring plan.
• The company has a history of losses and negative cash flow.

Risks

• The company faces macroeconomic risks such as inflation and recessionary conditions.
• There is substantial doubt about the company's ability to continue as a going concern due to recurring losses.
• The company may be unable to increase cash flow or raise sufficient capital.
• There are risks related to satisfying debt covenants and maintaining an active trading market for shares.
• The company is dependent on Neuronetics as its exclusive supplier of TMS devices.
• There are risks and uncertainties related to the completion of the Neuronetics acquisition.
• The company has a material weakness in its internal control over financial reporting.

Future Outlook

The company expects the Neuronetics acquisition to close in early December 2024 and believes the combined entity will accelerate the path to profitability. The company also plans to continue expanding its treatment offerings and streamline operations.

Management Comments

• With the imminent closing of the Neuronetics Transaction, we are excited to create a vertically-integrated organization capable of providing access to mental health treatment with significant scale in the United States.
• We believe the Neuronetics Transaction, coupled with our previously-announced Supplemental Restructuring Plan, will assist in accelerating our path to profitability.
• Looking to the future, we believe that mental health remains a key focus in the United States and the unmet demand for treatment remains at an all-time high.

Industry Context

The announcement reflects a trend of consolidation in the mental health services industry, with companies seeking to expand their reach and service offerings. The acquisition by Neuronetics aims to create a larger, more integrated provider of TMS therapy and related treatments.

Comparison to Industry Standards

• Greenbrook's revenue growth of 9% in Q3 2024 is a positive sign, but the increase in regional operating loss indicates challenges in cost management.
• Compared to other mental health service providers, Greenbrook's expansion into Spravato, medication management, and talk therapy is a strategic move to diversify revenue streams.
• The acquisition by Neuronetics is similar to other mergers in the healthcare sector, where companies combine to achieve economies of scale and market dominance.
• The restructuring plan, including the closure of 23 treatment centers, is a common strategy for companies facing financial difficulties, aiming to focus on core profitable operations.

Legal Proceedings

• The company settled a complaint in the Superior Court of the State of Delaware with Benjamin Klein, Success Behavioral Holdings, LLC, Theragroup LLC, Batya Klein and The Bereke Trust U/T/A dated 2/10/03.

Related Party Transactions

• The company has related party transactions with Madryn, Greybrook Health, and Benjamin Klein, including loans, share issuances, and service agreements.

Stakeholder Impact

• Shareholders will be impacted by the acquisition by Neuronetics, receiving shares in the combined company.
• Employees may be affected by the closure of 23 treatment centers as part of the restructuring plan.
• Patients will continue to receive treatment at the remaining 95 centers, with expanded offerings in some locations.
• Creditors will be impacted by the restructuring and the acquisition.

Next Steps

• The company expects to close the acquisition by Neuronetics in early December 2024.
• The company will continue to implement its supplemental restructuring plan, closing 23 treatment centers by the end of 2024.
• The company will focus on its remaining 95 treatment centers and continue to expand its treatment offerings.

Key Dates

Keywords

Transcranial Magnetic Stimulation, TMS, Spravato, Mental Health, Neuronetics, Acquisition, Restructuring, Financial Results, Depression, Treatment Centers